Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4VAOG)

• Drug Name: Gadobenate dimeglumine Drug Info
• Synonyms: Hydron; Multihance; Gadobenate Dimeglumine [USAN]; Gadobenic acid; Gadobenic acid dimeglumine salt; Meglumine gadobenate; Multihance Multipack; B 1903617; E-7155; Gadobenate dimeglumine (USAN); Gd-BOPTA; Meglumine gadobenate (JAN); Multihance (TN); B-19036/7; Gadolinium(3+); Gd-Bopta/dimeg; Dihydrogen ((+-)-4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-))gadolinate(2-), compound with 1-deoxy-1-(methylamino)-D-glucitol (1:2); (2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol; Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N5,N8,N11,O4,O5,O8,O11,O13)-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2); 2-[2-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]-3-phenylmethoxypropanoate; 2-[carboxymethyl-[2-[2-[carboxymethyl-(2-oxido-2-oxoethyl)amino]ethyl-(2-oxido-2-oxoethyl)amino]ethyl]amino]-3-phenylmethoxypropanoate; D-Glucitol, 1-deoxy-1-(methylamino)-, (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8), O(sup 11),O(sup 13)-gadolinate(2-) (2:1); Gadolinate(2-), (4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8,11-triazatridecan-13-oato(5-)-N(sup 5),N(sup 8),N(sup 11),O(sup 4),O(sup 5),O(sup 8),O(sup 11),O(sup 13))-, dihydrogen, comp. with 1-deoxy-1-(methylamino)-D-glucitol (1:2)

Indication

Disease Entry	ICD 11	Status	REF
Schizophrenia	6A20	Approved	[1] , [2] , [3]

• Therapeutic Class: Contrast Media
• Cross-matching ID:
  PubChem CID: 6918204
  CAS Number: CAS 127000-20-8
  TTD Drug ID: DM4VAOG
  VARIDT Drug ID: DR01257

Molecule-Related Drug Atlas

Drug(s) Transported By Multidrug resistance-associated protein 2 (ABCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Solid tumour/cancer	2A00-2F9Z	Approved	[6]
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[7]
Folic acid	DMEMBJC	Folate-deficiency anemia	3A02.Y	Approved	[8]
Fluorouracil	DMUM7HZ	Solid tumour/cancer	2A00-2F9Z	Approved	[9]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[10]
Cisplatin	DMRHGI9	Solid tumour/cancer	2A00-2F9Z	Approved	[11]
Acetaminophen	DMUIE76	Pain	MG30-MG3Z	Approved	[12]
Sulfasalazine	DMICA9H	Irritable bowel syndrome	DD91.0	Approved	[13]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[14]
Oxaliplatin	DMQNWRD	Colorectal cancer	2B91.Z	Approved	[15]

Drug(s) Transported By Organic anion transporting polypeptide 1B1 (SLCO1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[16]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[17]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[18]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[19]
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[18]
Pravastatin	DM6A0X7	Hypercholesterolaemia	5C80.0	Approved	[20]
Mycophenolate mofetil	DMPQAGE	Organ transplant rejection	NE84	Approved	[21]
Atorvastatin	DMF28YC	Cardiovascular disease	BA00-BE2Z	Approved	[22]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[23]
Pitavastatin calcium	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[20]

Drug(s) Transported By Organic anion transporting polypeptide 1B3 (SLCO1B3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	leukaemia	2A60-2B33	Approved	[24]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[18]
Etoposide	DMNH3PG	Solid tumour/cancer	2A00-2F9Z	Approved	[25]
Diclofenac	DMPIHLS	Osteoarthritis	FA00-FA05	Approved	[26]
Sorafenib	DMS8IFC	Hepatocellular carcinoma	2C12.02	Approved	[18]
Pravastatin	DM6A0X7	Hypercholesterolaemia	5C80.0	Approved	[27]
Mycophenolate mofetil	DMPQAGE	Organ transplant rejection	NE84	Approved	[21]
Atorvastatin	DMF28YC	Cardiovascular disease	BA00-BE2Z	Approved	[23]
Erythromycin	DM4K7GQ	Bacterial infection	1A00-1C4Z	Approved	[28]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[23]

Drug(s) Targeting Serum albumin (ALB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[29]
Oxyphenbutazone	DMPZS7U	Arthritis	FA20	Approved	[30]
Iodipamide	DMXIQYS	Gallbladder disease	DC11.3	Approved	[31]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[32]
Gadofosveset	DM5V9U1	Imaging	QA0B	Approved	[33]
Albumin Human	DM5JTPU	Hypoalbuminemia	5C53.2	Approved	[34]
Bismuth	DMTKU46	Diarrhea	ME05.1	Approved	[35]
EVANS BLUE	DM5GT1M	Abdominal aortic aneurysm	BD50.4	Approved	[36]
Activated recombinant FVII-albumin fusion protein	DMKY9GI	Hemophilia	3B10.0	Phase 2/3	[37]
Vobarilizumab	DM9KNJT	Rheumatoid arthritis	FA20	Phase 2	[38]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serum albumin (ALB)	TTFNGC9	ALBU_HUMAN	Binder	[4]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 2 (ABCC2)	DTFI42L	MRP2_HUMAN	Substrate	[5]
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[5]
Organic anion transporting polypeptide 1B3 (SLCO1B3)	DT9C1TS	SO1B3_HUMAN	Substrate	[5]

References

• [1] 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 021357.
• [4] Protocol design for high relaxivity contrast agents in MR imaging of the CNS. Eur Radiol. 2006 Nov;16 Suppl 7:M3-7.
• [5] Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes. Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):657-667.
• [6] Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
• [7] Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
• [8] Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
• [9] Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
• [10] Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
• [11] Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
• [12] Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
• [13] Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
• [14] Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
• [15] Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
• [16] Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
• [17] Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
• [18] Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
• [19] Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
• [20] The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
• [21] Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
• [22] Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
• [23] FDA Drug Development and Drug Interactions
• [24] LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
• [25] Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
• [26] Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
• [27] Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
• [28] Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
• [29] Some properties of the interaction between 2,2'-diselenadibenzoic acid and serum albumins. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):263-7.
• [30] Effect of albumin conformation on binding of phenylbutazone and oxyphenbutazone to human serum albumin. J Pharm Sci. 1982 Feb;71(2):241-4.
• [31] Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54.
• [32] Transport of ebselen in plasma and its transfer to binding sites in the hepatocyte. Biochem Pharmacol. 1994 Sep 15;48(6):1137-44.
• [33] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [34] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [35] Competitive binding of bismuth to transferrin and albumin in aqueous solution and in blood plasma. J Biol Chem. 2001 Mar 23;276(12):8829-35.
• [36] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [37] ClinicalTrials.gov (NCT01542619) A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers. U.S. National Institutes of Health.
• [38] Clinical pipeline report, company report or official report of Ablynx.